Comparison of bismuth quadruple therapy with Clarithromycin quadruple therapy in the treatment of Helicobacter pylori

Phase 4

Recruiting

• Conditions: Digestive System; Helicobacter pylori

• Registration Number: PACTR202304550587833
• Lead Sponsor: Galpharma

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-03-29
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Age 18 to 60 years.
Patients with H. pylori infection documented by pathological evidence (gastric biopsy), by breath test or by H. pylori Antigen in stool and who have never received H. pylori eradication treatment.
Patients who gave informed consent for participation in our research.

Exclusion Criteria

Patient has serious underlying diseases such as hepatic failure, renal failure , immunosuppression, malignancies, coronary artery disease, or severe psychiatric or neurological disorders.
The patient is a pregnant or lactating woman.
Patient has active gastrointestinal bleeding or a history of upper gastrointestinal surgery.
The patient is allergic to the drugs in the treatment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified